Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the safety and tolerability of triheptanoin in participants with Rett syndrome using laboratory values, electrocardiogram, rate of adverse events (AE), and physical exam.This study also seeks to evaluate the efficacy of UX007 (triheptanoin) in improving overall seizure frequency and dystonia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome.

NCT03059160

Rett Syndrome

UNKNOWN PHASE2

Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome

NCT02000960

Glucose Transporter Type 1 Deficiency Syndrome

UNKNOWN PHASE2

An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome

NCT02036853

Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)

COMPLETED PHASE2

Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects

NCT00122044

Dystonia

COMPLETED PHASE2

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

NCT06554288

Pediatric Disorder Genetic Predisposition Dystonia, Secondary +5 more

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to evaluate the safety and tolerability of triheptanoin in participants with Rett syndrome using laboratory values, electrocardiogram, rate of adverse events (AE), and physical exam. This study also seeks to evaluate the efficacy of UX007 (triheptanoin) in improving overall seizure frequency, dystonia severity, and quality of life. Participants who are eligible will take triheptanoin daily. Participation in the primary arm of this study will last up to 8.5 months, with an optional 36 month extension.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rett Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants aged 0 months to 3 years

Participants will receive 4 grams of triheptanoin per kilogram of body weight daily.

Group Type EXPERIMENTAL

triheptanoin

Intervention Type DRUG

Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.

Participants aged 4 to 6 years

Participants will receive 3 grams of triheptanoin per kilogram of body weight daily.

Group Type EXPERIMENTAL

triheptanoin

Intervention Type DRUG

Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.

Participants aged 7 to 9 years

Participants will receive 2.5 grams of triheptanoin per kilogram of body weight daily.

Group Type EXPERIMENTAL

triheptanoin

Intervention Type DRUG

Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.

Participants aged 10 to 14 years

Participants will receive 2 grams of triheptanoin per kilogram of body weight daily.

Group Type EXPERIMENTAL

triheptanoin

Intervention Type DRUG

Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.

Participants aged 15 to 20 years

Participants will receive 1.5 grams of triheptanoin per kilogram of body weight daily.

Group Type EXPERIMENTAL

triheptanoin

Intervention Type DRUG

Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.

Participants aged 21 years and older

Participants will receive 1.2 grams of triheptanoin per kilogram of body weight daily.

Group Type EXPERIMENTAL

triheptanoin

Intervention Type DRUG

Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

triheptanoin

Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Classic Rett syndrome as defined by the clinical consensus criteria
* Presence of a MECP2 mutation
* Post-regression stage of development, defined as greater than 6 months since the last loss of hand use or verbal language
* Average of at least 4 observable seizures (generalized or partial-onset \[Generalized Tonic-Clonic, Generalized Tonic, Generalized Clonic, Generalized Atonic, Partial/Focal with Secondary Generalization, Myoclonic, Myoclonic Atonic, Myoclonic Tonic, Complex Partial/Focal, and Simple Partial/Focal Motor) in one month prior to the study by caregiver report or presence of dystonia on average at least four times in one month prior to the study in at least one body region rated as at least "mild" by caregiver report
* Use of at least one anti-seizure medication at screening visit
* At screening visit, managed on four or fewer concomitant anti-seizure medications that must have been stable in dose at least one month prior to the beginning of screening and anticipated to remain stable in dose through the end of the 8.5 month trial period
* Legally authorized caregiver must be willing to give written informed consent after the nature of the study has been explained, and prior to any research-related procedures
* Caregiver and participant must, in the opinion of the investigator, be willing and able to complete all aspects of the study, comply with accurate completion of the seizure and dystonia diaries, and be likely to complete the four month treatment period

Exclusion Criteria

* Markedly abnormal metabolic screening laboratory testing (e.g., serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 2X the upper limit of normal)
* Any known hypersensitivity to triheptanoin that, in the judgment of the investigator, places the subject at increased risk for adverse effects
* Prior use of triheptanoin within 1 month prior to screening
* Participants or caregivers who are unwilling or unable to discontinue use of a prohibited medication or other substance that may confound study objectives
* Use of any other investigational product, including drugs or supplements within 1 month prior to Screening, or at any time during the study
* Has a condition of such severity and acuity, in the opinion of the investigator, that it warrants immediate surgical intervention or other treatment
* Has a concurrent disease or condition, or laboratory abnormality that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or introduces additional safety concerns (e.g., diabetes mellitus)
* Pregnant or nursing women

Minimum Eligible Age

2 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No